Health Canada authorizes P-I clinical trial of Mod...
August 10, 2026
Takeaways: Health Canada’s decision makes Nucala the first biologic add‑on for eosinophilic COPD in Canada, opening a new high-value segment on top of triple inhaled therapy for patients with fr...
The world’s population is aging at an unprecedented pace, creating one of the most significant long term shifts in global healthcare demand. By the coming decades, older adults will represent an incre...
Takeaways: If approved, FILSUVEZ would become Canada’s first treatment specifically for EB-related wounds, addressing a severe unmet need for patients with chronic, painful skin breakdown and he...
Takeaways: This accelerates Italfarmaco’s commercial entry, giving it a platform to negotiate reimbursement and patient access with a distinct HDAC-inhibitor mechanism and a combinatio...
Takeaways: UM171 was discovered at Université de Montréal, so this deal keeps a Canadian‑origin innovation tied to a Canadian commercial partner, aligning with domestic priorities around life‑sc...
Takeaways: Kashiv BioSciences gets a key regulatory step for its XOLAIR (omalizumab) biosimilar, ADL-018. The market implication is a likely cost-reduction play in a high-value o...
Patient centricity has become one of the most widely used, and often overused, terms in the biopharma industry. In Canadian Health discussions, nearly every stakeholder references it in some form, emb...
Takeaways: This notice of allowance shores up Anixa’s IP moat around its AMHR2‑targeted ovarian cancer vaccine and aligns Canada with its existing US patent protection. ...
Takeaways: Sunshine Biopharma’s approval for generic rivaroxaban (Xarelto) adds a high-volume, key anticoagulant to its Canadian portfolio and pairs with its existing generic apixaban to create ...
Takeaways: This acquisition turbocharges Hims & Hers’ Canada growth by giving it a ready-made weight-management business and local provider network, while it becomes the first Canadian...
